Filter
42
Filtered Results: 42
Text search:
GARDP
Global
Acntibiotic
Research
&
Dedvelopment
Partnership
Featured
Recommendations
4
New Publications
11
Language
Document type
Studies & Reports
20
No document type
7
Situation Updates
6
Guidelines
3
Manuals
2
Strategic & Response Plan
2
Training Material
1
Resource Platforms
1
Countries / Regions
South Africa
4
Nigeria
3
Nepal
2
Kenya
2
Global
2
Tanzania
2
Ethiopia
2
Thailand
1
Burkina Faso
1
Peru
1
Zimbabwe
1
Philippines
1
Mozambique
1
Asia
1
Jordan
1
Bangladesh
1
Vietnam
1
Uganda
1
Namibia
1
India
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Studies & Reports
5
Pediatrics
2
Drugs & Medical Equipment
2
Paediatrics
1
Medical Devices & Equipment
1
Policies
1
Guidelines
1
Community Health
1
Toolboxes
Country Specific
8
Country specific
6
Studies
6
Supporting tools
4
General
4
Sustainable Development Goals
2
International
2
Stewardship
2
Local Action
1
Surveillance
1
Agriculture & Veterinary
1
Platforms and initiatives
1
Health Equity & Equality
1
Research & Development
1
Livestock production
1
Strategies & Roadmaps
1
Asia and Pacific
1
General Public
1
Assessment
1
AMR
1
Reports & Studies
1
This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ...
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac...
This National Action Plan addresses actions needed to be taken in order to combat antimicrobial resistance (AMR) in the country. It is obligatory to raise awareness of antimicrobial resistance and promote behavioral change through public communication
programmes that targets human, animal and plant...
Nepal has only recently started its journey on the path to an integrated response to the challenge of antimicrobial resistance (AMR). Despite this, it is notable that the Nepal Health Sector Strategy Plan (HSSP)-2 mentions growing antibiotic resistanceas a public health challenge.
The most significant finding of the case study for integrating antimicrobial resistance (AMR)into existing programs and mobilising resources for funding in Nigeria, is that most of the AMR activities within the Nigerian National Action Plan (NAP)canalready be incorporated within exi...
Global actions to reduce antimicrobial resistance (AMR) include optimising the use of antimicrobial medicines in human and animal health. In countries with weak healthcare regulation, this requires a greater understanding of the drivers of antibiotic use from the perspective of providers and consume...
Antibiotics and other antimicrobial agents are invaluable life savers, particularly in resource-limited countries where infectious diseases are abundant. Both uncomplicated and severe infections are potentially curable as long as the aetiological agents are susceptible to the ...
The Global Antibiotic Resistance Partnership (GARP) aims to address the challenge of antibiotic resistance by developing actionable Policy Proposals in Vietnam and four other low- and middle-income countries: China, India, Kenya and South Africa. GARP will develop the evidence base for Policy action...
Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet...
The Global Antibiotic Resistance Partnership (GARP)-Mozambique team, in partnership with the Center for Disease Dynamics, Economics & Policy (CDDEP), has produced this report as part of a solid com-mitment to develop actionable policy proposals to tackle antibiotic resistance and improve appropriate...
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ...
Antibiotic resistance is no longer a concern for the distant future but is a pressing issue, both globally and in Nepal. As part of global effort to preserve the effectiveness of antibiotics, the Global Antibiotic Resistance Partnership (GARP)-Nepal was established to doc...
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we ...
Antimicrobial resistance (AMR) is a multifaceted, international public health problem, which poses a direct threat to the safety of the population of South Africa. A national response is required to complement the development of a global plan, as articulated in the WHO’s draft resolution EB134/37 ...
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent...
